CMPX
Compass Therapeutics, Inc.
$2.03
+1.00%
$365.6M
No data for this timeframe.
Vol
Market Cap$365.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders50 funds
Inst. Value$297.0M
Inst. Activity22 buys / 5 sells
Reddit Sentiment52° Neutral
SEC Reports5
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001738021·Prev Close $2.01
Recent Activity
Jun 11, 2026
SEC
A mixed institutional cluster in CMPX for Q3 2024 shows 6 buyers accumulating $11.0M net (led by Blackstone adding $10.8
INST-CLUSTER — Impact 4/10
May 28, 2026
other
Compass Therapeutics to Participate in Upcoming June Investor Events
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX)
May 5, 2026
SEC
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.10 consensus estimat
8-K — Impact 7/10
Apr 29, 2026
SEC
Compass Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on April 29, 2026. The filing co
DEFA14A — Impact 4/10
Apr 29, 2026
Insider
Lerner Neil was granted 15,000 shares
Chief Accounting Officer @ $1.89 ($28.4K)
Apr 29, 2026
Insider
Anderman Jonathan was granted 25,000 shares
General Counsel @ $1.89 ($47.3K)
Feb 8, 2026
Insider
Schuetz Thomas J. surrendered for taxes 36,687 shares
CHIEF EXECUTIVE OFFICER @ $6.52 ($239.2K)
Inst.
ADAGE CAPITAL PARTNERS GP, — ADD
8,486,500 shares ($44.9M)
Price Targets
$8.82
+334.4% upside
Strong Buy
Current $2.03
Low $4.00
Median $7.00
High $24.00
11 analysts
$4.00
$24.00
Analyst Ratings
8Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform → Market Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▼ -9.1% | $-0.15 — $-0.09 | 22% YoY | 11 |
| Next Q | $-0.11 ▲ +8.6% | $-0.12 — $-0.08 | -33% YoY | 11 |
| Current FY | $-0.44 ▼ -2.1% | $-0.59 — $-0.33 | -4% YoY | 11 |
| Next FY | $-0.46 ▼ -13.0% | $-0.82 — $-0.13 | -5% YoY | 11 |
Latest Reports
MIXED
INST-CLUSTER
4/10
A mixed institutional cluster in CMPX for Q3 2024 shows 6 buyers accumulating $11.0M net (led by Blackstone adding $10.8
Jun 11, 2026
BULLISH
Press
7/10
Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation data for CTX-8371, a P
May 21, 2026
BULLISH
8-K
7/10
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.10 consensus estimat
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| BlackRock, Inc. | $50.3M | ADD |
| ADAGE CAPITAL PARTNERS GP, | $44.9M | ADD |
| STATE STREET CORP | $35.4M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.9M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 29, 2026 | Lerner Neil | A | $28.4K |
| Apr 29, 2026 | Anderman Jonathan | A | $47.3K |
| Feb 8, 2026 | Schuetz Thomas | F | $239.2K |
Reddit Sentiment
52°▲
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $297.0M total value (56,140,327 shares) as of 2026-Q1. Top holders: ROYAL, BlackRock,, ADAGE. Net buying activity: 22 institutions added/increased vs 5 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 6 | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 9,506,080 | $50.3M | 16.9% | ADD +27.4% |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 8,486,500 | $44.9M | 15.1% | ADD +91.3% |
| 4 | STATE STREET CORP | 6,694,976 | $35.4M | 11.9% | ADD +36.9% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6,037,175 | $31.9M | 10.8% | — |
| 6 | RTW INVESTMENTS, LP | 4,186,599 | $22.1M | 7.5% | ADD +67.5% |
| 7 | GOLDMAN SACHS GROUP INC | 1,995,394 | $10.6M | 3.6% | — |
| 8 | Blackstone Inc. | 1,857,848 | $9.8M | 3.3% | TRIM -69.7% |
| 9 | FMR LLC | 1,801,721 | $9.5M | 3.2% | TRIM -30.2% |
| 10 | ROYCE & ASSOCIATES LP | 1,619,798 | $8.6M | 2.9% | DOUBLED +466.4% |
| 11 | AMERIPRISE FINANCIAL INC | 1,596,815 | $8.4M | 2.8% | ADD +94.0% |
| 12 | BALYASNY ASSET MANAGEMENT L.P. | 1,119,090 | $5.9M | 2.0% | TRIM -29.8% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,082,651 | $5.7M | 1.9% | — |
| 14 | VANGUARD FIDUCIARY TRUST CO | 998,140 | $5.3M | 1.8% | — |
| 15 | BANK OF AMERICA CORP /DE/ | 865,613 | $4.6M | 1.5% | DOUBLED +224.9% |
| 16 | BARCLAYS PLC | 790,041 | $4.2M | 1.4% | — |
| 17 | CITADEL ADVISORS LLC | 721,410 | $3.8M | 1.3% | — |
| 18 | CITIGROUP INC | 598,238 | $3.2M | 1.1% | — |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 497,818 | $2.6M | 0.9% | DOUBLED +159.7% |
| 20 | PRUDENTIAL FINANCIAL INC | 494,300 | $2.6M | 0.9% | ADD +57.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 4,436,500 | 8,486,500 | +91.3% | $44.9M | 2026-Q1 |
| STATE STREET CORP | ADD | 4,890,525 | 6,694,976 | +36.9% | $35.4M | 2026-Q1 |
| RTW INVESTMENTS, LP | ADD | 2,500,000 | 4,186,599 | +67.5% | $22.1M | 2026-Q1 |
| Blackstone Inc. | TRIM | 6,126,182 | 1,857,848 | -69.7% | $9.8M | 2026-Q1 |
| FMR LLC | TRIM | 2,579,711 | 1,801,721 | -30.2% | $9.5M | 2026-Q1 |
| ROYCE & ASSOCIATES LP | DOUBLED | 285,988 | 1,619,798 | +466.4% | $8.6M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 823,174 | 1,596,815 | +94.0% | $8.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 1,593,275 | 1,119,090 | -29.8% | $5.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 266,434 | 865,613 | +224.9% | $4.6M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 191,724 | 497,818 | +159.7% | $2.6M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 314,750 | 494,300 | +57.0% | $2.6M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 341,596 | 439,784 | +28.7% | $2.3M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | DOUBLED | 22,629 | 375,320 | +1558.6% | $2.0M | 2026-Q1 |
| Rafferty Asset Management, LLC | ADD | 151,743 | 195,867 | +29.1% | $1.0M | 2026-Q1 |
| Invesco Ltd. | ADD | 63,901 | 101,207 | +58.4% | $535.4K | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 12,753 | 75,103 | +488.9% | $397.3K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 40,325 | 67,466 | +67.3% | $356.9K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 5,244 | 30,229 | +476.4% | $159.9K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 14,900 | 25,100 | +68.5% | $132.8K | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 12,807 | 16,353 | +27.7% | $86.5K | 2026-Q1 |
| M&T BANK CORP | NEAR_EXIT | 764,229 | 15,043 | -98.0% | $79.6K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 413 | 11,038 | +2572.6% | $58.4K | 2026-Q1 |
| Brevan Howard Capital Management LP | NEAR_EXIT | 118,528 | 10,200 | -91.4% | $54.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 2,042 | 10,182 | +398.6% | $53.9K | 2026-Q1 |
| CWM, LLC | ADD | 3,059 | 4,317 | +41.1% | $22.8K | 2026-Q1 |
3 unique insiders with 3 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Lerner Neil | Chief Accounting Officer | AWARD | 15,000 | $1.89 | $28.4K |
| Apr 29, 2026 | Anderman Jonathan | General Counsel | AWARD | 25,000 | $1.89 | $47.3K |
| Feb 8, 2026 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | TAX W/H | 36,687 | $6.52 | $239.2K |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 5.8/10.
MIXED
INST-CLUSTER
4/10
A mixed institutional cluster in CMPX for Q3 2024 shows 6 buyers accumulating $11.0M net (led by Bla
Jun 11, 2026
BULLISH
8-K
7/10
Compass Therapeutics reported Q1 2026 net loss of $18.3M ($0.10/share), slightly better than the $0.
May 5, 2026
NEUTRAL
DEFA14A
4/10
Compass Therapeutics filed a DEFA14A (additional definitive proxy soliciting materials) on April 29,
Apr 29, 2026
BULLISH
8-K
7/10
Compass Therapeutics announced positive Phase 2/3 trial data for tovecimig in biliary tract cancer,
Apr 27, 2026
MIXED
8-K, PRESS-RELEASE
7/10
Compass Therapeutics reported its 2025 financial results and provided a corporate update, highlighti
Mar 5, 2026
BULLISH
7/10
Compass Therapeutics announced a poster presentation at ASCO 2026 showing Phase 1 dose-escalation da
May 21, 2026
BULLISH
8/10
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, achieved a highly sta
Apr 27, 2026
NEUTRAL
5/10
Compass Therapeutics (CMPX) will host a webcast on April 27, 2026, to present topline secondary endp
Apr 24, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 8 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.82 mean target
+334.4% upside
Strong Buy (1.29)
$4.00 Low
$24.00 High
| Metric | Value |
|---|---|
| Current Price | $2.03 |
| Target Low | $4.00 |
| Target Mean | $8.82 |
| Target Median | $7.00 |
| Target High | $24.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.15 | $-0.09 | 22.1% | -9.1% | 0↑ 3↓ | $-0.0B | 0.0% | 11 |
| Next Q 2026-09-30 |
$-0.11 | $-0.12 | $-0.08 | -33.0% | +8.6% | 0↑ 2↓ | $0.0B | 0.0% | 11 |
| Current FY 2026-12-31 |
$-0.44 | $-0.59 | $-0.33 | -3.9% | -2.1% | 1↑ 2↓ | $-0.0B | 0.0% | 11 |
| Next FY 2027-12-31 |
$-0.46 | $-0.82 | $-0.13 | -5.4% | -13.0% | 0↑ 6↓ | $0.0B | 1258.9% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.109 | |
| 7d ago | $-0.109 | |
| 30d ago | $-0.100 | -0.009 |
| 60d ago | $-0.096 | -0.013 |
| 90d ago | $-0.088 | -0.021 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 28, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Citizens | REITERATE | Market Outperform | Market Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 27, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Jan 6, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | William Blair | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 10 | 2 | 0 | 0 | 90% | |
| May 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 9 | 12 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 9 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
52°
Neutral
Bearish
Neutral
Bullish
23 mentions
7 bullish
6 bearish
21 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 29, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
CMPX WILL FLY TOMORROW!
▲ 1
💬 1
⚡ 0.1
CMPX WILL FLY TOMORROW
▲ 1
💬 1
⚡ 0.2
CMPX TOMORROW
▲ 1
💬 1
⚡ 0.5
CMPX IS A STOCK TO WATCH!
▲ 1
💬 0
⚡ 0.5
CMPX is A stock to watch!
▲ 1
💬 1
⚡ 0.5
CMPX is a stock to watch!
▲ 1
💬 1
⚡ 0.5
CMPX!!!!!!!!!!
▲ 1
💬 0
⚡ 0.5
CMPX!!!!!!!
▲ 1
💬 0
⚡ 0.5
$CMPX: Upcoming catalyst Pre-BLA Meeting, $195M War Chest, and the Crossover Nobody's Talking About;
▲ 1
💬 1
⚡ 0.5
Thoughts on CMPX 65% drop
▲ 1
💬 0
⚡ 0.5
Thoughts on CMPX 65% drop
▲ 1
💬 1
⚡ 0.5
May 28, 2026
other
Compass Therapeutics to Participate in Upcoming June Investor Events
<p align="left">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceut
May 21, 2026
fda
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
<p>BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
May 17, 2026
Clinical Trial
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Phase Phase 2 — COMPLETED
May 13, 2026
earnings_calendar
CMPX Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
other
Compass Therapeutics to Participate in Upcoming May Investor Events
<p>BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
May 8, 2026
short_interest
FTD: CMPX — 1,450,764 shares ($2.6M) failed to deliver
Settlement: 20260508, Price: $1.81, FTD Value: $2,625,882.84, COMPASS THERAPEUTICS INC COM
May 6, 2026
earnings_calendar
CMPX Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
<p>BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company
Apr 30, 2026
Clinical Trial
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Phase Phase 3 — COMPLETED
Apr 27, 2026
fda
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig Demonstrates Significant Benefit in Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Apr 24, 2026
fda
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
<p>BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical compan
Apr 24, 2026
short_volume
Short Volume: CMPX — 73.2% short (1.1M / 1.5M)
Short: 1,109,621 | Exempt: 8,914 | TRF Vol: 1,515,014 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: CMPX — 74.5% short (0.5M / 0.6M)
Short: 482,068 | Exempt: 0 | TRF Vol: 647,359 | Short Ratio: 74.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: CMPX — 61.7% short (0.7M / 1.1M)
Short: 699,402 | Exempt: 5,680 | TRF Vol: 1,132,882 | Short Ratio: 61.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_interest
FTD: CMPX — 99,932 shares ($0.6M) failed to deliver
Settlement: 20260420, Price: $6.00, FTD Value: $599,592, COMPASS THERAPEUTICS INC COM
Apr 20, 2026
short_volume
Short Volume: CMPX — 62.0% short (0.8M / 1.4M)
Short: 840,535 | Exempt: 59,522 | TRF Vol: 1,354,910 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_interest
FTD: CMPX — 93,631 shares ($0.6M) failed to deliver
Settlement: 20260417, Price: $6.53, FTD Value: $611,410.43, COMPASS THERAPEUTICS INC COM